Program
Lamivudine
Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.
Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 352 open or running | phase 4since Feb 15, 2000 | Nov 2, 1999 | Sep 14, 2032phase 3 · NCT07393659 |
| Bristol-Myers Squibbits history only | 70 open or running | phase 4since Jun 27, 2005 | Nov 2, 1999 | none ahead |
| Abbottits history only | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Dupont Merckits history only | 20 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| triangle-pharmaceuticalsits history only | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Nov 2, 1999.
- Oct 24, 2007Phase 4 study in InfectionsNCT00549198 · 392 enrolled · Austria, Belgium, Denmark and more
- Jul 25, 2013Phase 3 study in InfectionsNCT01910402 · 499 enrolled · United States, Argentina, Canada and more
- Apr 3, 2014Phase 3 study in InfectionsNCT02105987 · 555 enrolled · United States, Canada, Puerto Rico
- Dec 14, 2015Phase 4 study in InfectionsNCT02634073 · 16 enrolled · United States
- Apr 11, 2016Phase 1 study in InfectionsNCT02738931 · 30 enrolled · United States
- Jul 8, 20162 phase 3 studies in InfectionsNCT02831764, NCT02831673
- Mar 8, 2017Phase 1 study in InfectionsNCT03078556 · 154 enrolled · United States
- Jan 5, 2018Phase 3 study in HIV InfectionsNCT03446573 · 743 enrolled · United States, Australia, Belgium and more
- Sep 21, 2018Phase 3 study in HIV InfectionsNCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
- May 8, 2019Phase 3 study in HIV InfectionsNCT03945981 · 131 enrolled · United States
- Jul 11, 2019Phase 3 study in HIV InfectionsNCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
- Jun 9, 20232 phase 3 studies in HIV InfectionsNCT05911360, NCT05917509
- Jul 19, 2023Phase 3 study in HIV InfectionsNCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
- Jan 30, 2026Phase 3 study in HIV InfectionsNCT07393659 · 197 planned · Romania, South Africa, Uganda
Ahead
- Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsNCT07393659
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 35 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07393659HIV Infections · Romania, South Africa, Uganda | 3 | Recruiting | Sep 14, 2032 | 197 |
| NCT05979311HIV Infections · Argentina, Belgium, Denmark and more | 3 | Active, not recruiting | Apr 15, 2026 | 463 |
| NCT05917509HIV Infections · United States, Argentina, Canada and more | 3 | Completed | Sep 16, 2025 | 171 |
| NCT05911360HIV Infections · United States, Austria, Belgium and more | 3 | Completed | Jan 23, 2026 | 205 |
| NCT04021290HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | Apr 23, 2021 | 493 |
| NCT03945981HIV Infections · United States | 3 | Completed | Apr 29, 2020 | 131 |
| NCT03682848HIV Infections · Kenya, South Africa, Thailand | 3 | Completed | Dec 1, 2021 | 32 |
| NCT03446573HIV Infections · United States, Australia, Belgium and more | 3 | Completed | May 20, 2019 | 743 |
| NCT03078556Infections · United States | 1 | Completed | Aug 18, 2017 | 154 |
| NCT02831764Infections · United States, Argentina, Australia and more | 3 | Completed | Apr 4, 2018 | 722 |
| NCT02831673Infections · United States, Argentina, Australia and more | 3 | Completed | Mar 29, 2018 | 719 |
| NCT02738931Infections · United States | 1 | Completed | Jun 2016 | 30 |
| NCT02634073Infections · United States | 4 | Completed | Mar 1, 2016 | 16 |
| NCT02105987Infections · United States, Canada, Puerto Rico | 3 | Completed | Apr 2015 | 555 |
| NCT01910402Infections · United States, Argentina, Canada and more | 3 | Completed | Sep 22, 2015 | 499 |
| NCT00549198Infections · Austria, Belgium, Denmark and more | 4 | Completed | Dec 2009 | 392 |
| NCT00440947Infections · United States, Canada, Puerto Rico | 3 | Completed | Jul 2010 | 515 |
| NCT00354653Hepatitis B, Chronic · Iran, Islamic Republic of | 4 | Completed | Jan 23, 2007 | 100 |
| NCT00337922HIV Infections · Japan | 4 | Completed | 8 | |
| NCT00140725Hepatitis B, Chronic · Hong Kong | 3 | Completed | 160 | |
| NCT00085943HIV Infections · United States, Austria, Belgium and more | 3 | Completed | 866 | |
| NCT00046176Infections · United States, Costa Rica, Panama and more | 3 | Completed | May 17, 2004 | 240 |
| NCT00011895HIV Infections · United States | 4 | UNKNOWN | 400 | |
| NCT00009061HIV Infections · United States | 3 | UNKNOWN | 624 | |
| NCT00005106HIV Infections · United States | 4 | Completed | 230 | |
| NCT00004981HIV Infections · United States | 3 | UNKNOWN | 230 | |
| NCT00004852HIV Infections · United States, Argentina, Brazil and more | 2 | Completed | ||
| NCT00004585HIV Infections · United States | 4 | Completed | 40 | |
| NCT00002442HIV Infections · United States | 2 | Completed | ||
| NCT00002436HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | 325 | |
| NCT00002409HIV Infections · United States | 3 | Completed | 200 | |
| NCT00002391HIV Infections · United States | 3 | Completed | ||
| NCT00002389HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | 210 | |
| NCT00002320HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | 320 | |
| NCT00002108HIV Infections · United States | – | Completed |
How it is read
Names in the registry
- “Lamivudine”, 35 entries
- “Lamivudine/Zidovudine”, 6 entries
- “Lamivudine (3TC)”, 4 entries
- “lamivudine”, 3 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 53 studies
- Acquired Immunodeficiency Syndrome, 8 studies
- Hepatitis B, Chronic, 6 studies
- Infections, 4 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.